A drug class that barely registered five years ago now dominates the high-cost list on most employer scorecards.
Run a pharmacy analysis on almost any employer population today and the same names surface near the top: Mounjaro, Ozempic, Wegovy, Victoza, Saxenda, Trulicity. On a representative scorecard, six of the top ten high-cost drugs were GLP-1 class therapies — at low utilization. That is the defining characteristic of this category: it moves trend materially even when very few people are taking it.
Why low utilization still breaks the budget
A handful of claimants on a branded GLP-1 can shift total pharmacy spend in a way that a hundred claimants on generic maintenance medication cannot. The per-member figure looks manageable; the per-claimant figure does not. Employers who budget on averages get surprised.
The coverage question has three answers, not two
The instinct is to frame this as cover-or-exclude. In practice, most employers land somewhere in between:
- Cover for diabetes indications only. Drugs approved for Type 2 diabetes remain covered under standard pharmacy benefits; weight-management indications are excluded. The cleanest line, though it creates real friction when the same molecule is prescribed for different reasons.
- Cover with clinical criteria. BMI thresholds, prior authorization, and documented participation in a lifestyle or coaching program. Most common among employers who want to offer access without an open-ended commitment.
- Cover with a managed pathway. Coverage paired with adherence support, step therapy where clinically appropriate, and periodic reauthorization. Highest administrative effort, best long-term cost behavior.
Levers beyond the coverage decision
Manufacturer assistance review
Savings-card and patient-assistance programs apply to several branded therapies in this class. It is worth reviewing systematically rather than leaving it to individual members to discover.
Formulary and therapeutic alternatives
A clinically reviewed formulary alternative can meaningfully reduce net cost where the alternative is appropriate for the indication. This is a clinical judgment, not a purchasing one — which is why it belongs with your pharmacy consultant rather than in a spreadsheet.
Adherence, not just access
Roughly one in five participants discontinued oral GLP-1 therapy during clinical trials. Discontinuation after the plan has absorbed the ramp-up cost is the worst of both outcomes — spend without benefit. Programs that support persistence protect the investment you already made.
Site of care for infused therapies
Not a GLP-1 issue specifically, but it surfaces on the same page of most scorecards. Infused therapies administered in hospital outpatient settings often cost multiples of the same drug delivered in an infusion center or at home.
What to do before your next renewal
- Quantify your actual exposure — claimant counts and net cost, not list price.
- Confirm what your current plan covers, by indication, in writing.
- Review assistance and formulary options with your pharmacy consultant.
- Decide your position deliberately, and communicate it to employees before open enrollment rather than after a denial.
The employers handling this well are not the ones who picked the most restrictive policy. They are the ones who decided on purpose, documented the rationale, and told employees what to expect.
This article is provided for informational purposes only and does not constitute legal, tax or benefits advice. Requirements vary by plan design, funding arrangement and jurisdiction. Contact BeneSkill to discuss how this applies to your plan.